Junko Tanizaki
0000-0002-6727-9435
Publication & Citation Trends
Most Cited Works
Publications
260 total
KRAS Inhibitor Resistance in <i>MET</i> -Amplified <i>KRAS</i> G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms PDF
Cited by 103
OpenAlex
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer PDF
Cited by 89
OpenAlex
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer
Cited by 238
OpenAlex
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment PDF
Cited by 293
OpenAlex
Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
Cited by 225
OpenAlex
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer
Cited by 169
OpenAlex
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors PDF
Cited by 129
OpenAlex
Report of two cases of pseudoprogression in patients with non–small cell lung cancer treated with nivolumab—including histological analysis of one case after tumor regression
Cited by 80
OpenAlex
Research Topics
Lung Cancer Treatments and Mutations
(176)
Lung Cancer Research Studies
(87)
HER2/EGFR in Cancer Research
(81)
Cancer Immunotherapy and Biomarkers
(52)
Protein Tyrosine Phosphatases
(19)
Frequent Co-Authors
Affiliations
Harvard University
Yamaguchi University
Kindai University Hospital
Kishiwada City Hospital
Kindai University Sakai Hospital